Rani Therapeutics Files Q1 2025 10-Q
Ticker: RANI · Form: 10-Q · Filed: May 13, 2025 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Rani Therapeutics Q1 2025 10-Q filed. R&D expenses noted for Q1 2024. Equity balances updated.
AI Summary
Rani Therapeutics Holdings, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported research and development expenses for the first quarter of 2024. Financial statements show balances for common stock, additional paid-in capital, and accumulated other comprehensive loss as of March 31, 2025.
Why It Matters
This filing provides investors with an update on Rani Therapeutics' financial performance and position as of the first quarter of 2025, including key expense categories and equity details.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Rani Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 001-40672 — SEC File Number (SEC file number for Rani Therapeutics Holdings, Inc.)
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 2024-01-01 2024-03-31 (date) — Period for which Research and Development Expenses were reported
- 2025-03-31 (date) — Balance sheet date
FAQ
What were Rani Therapeutics' research and development expenses for the first quarter of 2024?
The filing indicates that Research and Development Expense was reported for the period of 2024-01-01 to 2024-03-31.
What is the company's fiscal year end?
The company's fiscal year ends on 1231.
What is the company's primary business address?
The company's business address is 2051 RINGWOOD AVENUE, SAN JOSE, CA 95131.
What is the filing date of this 10-Q report?
This 10-Q report was filed on 20250513.
What are some of the equity components reported as of March 31, 2025?
As of March 31, 2025, the filing shows balances for us-gaap:CommonStockMember, us-gaap:AdditionalPaidInCapitalMember, and rani:AccumulatedOtherComprehensiveLossMember.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Rani Therapeutics Holdings, Inc. (RANI).